Click Here to Register »

2018 Agenda

  • Discovery & Preclinical Plenary Session

  • NK Cell CARs

    Dario Campana, MD, PhD

    Mrs Lee Kong Chian Chair in Advanced Cellular Therapy; Professor, Department of Pediatrics; Director, Division of Immunopathology and Cell Therapy
    National University of Singapore

  • Target Discovery for CAR-Ts and TCRs

    Laura Johnson, PhD

    Senior Director, Head Translational Medicine, Oncology Cell Therapy, GlaxoSmithKline

  • IDO plus Keytruda in Metastatic Myeloma

  • Early Clinical Data: Dual Targeting PDL1 and TGF Beta

    Julius Strauss, MD

    Director, Clinical Trials Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute

  • Investor Relations in Immunotherapy Plenary Session

  • Plenary Keynote: Evaluation and Forecast of the IO Space

    Andrew Baum, MD

    Head of Global Healthcare; Managing Director, Equity Research, Citi

  • Venture Capitalist Perspective on the IO Landscape

    Bruce Booth, DPhil

    Partner, Atlas Venture

  • Investor Roundtable: The Role of IO within Large Pharma - Where Does it Stand?


    Axel Hoos
    Axel Hoos, MD, PhD

    SVP, Oncology R&D, GlaxoSmithKline


    Andrew Baum, MD

    Head of Global Healthcare; Managing Director, Equity Research, Citi

    Bruce Booth, DPhil

    Partner, Atlas Venture

    Ali Behbahani, MD

    Partner, New Enterprise Associates

    Simeon George, MD

    Partner, SR One Ltd

  • Translational Science and Biomarkers Plenary Session

  • The Role of Antibody Isotypes for Agonist Antibodies - ICOS

    Patrick Mayes, PhD

    Director & Early Development Leader, GlaxoSmithKline

  • Immune Suppression in The Tumor Micro-environment: The Adenosine Pathway

    Ian McCaffery, PhD

    VP, Translational Science, Corvus Pharmaceuticals

  • MORPHEUS Novel CIT Platform to Address Multiple Combinations

    William Grossman, MD, PhD

    Global Development Leader, Cancer Immunotherapy Combinations, Genentech

  • Update on Cancer Vaccination and Biomarkers of Response

    Lisa Butterfield
    Lisa Butterfield, PhD

    Professor of Medicine, Surgery and Immunology Director, UPCI Immunologic Monitoring and Cellular Products Laboratory / President, University of Pittsburgh / Society for Immunotherapy of Cancer (SITC)

  • Using TC Clonality Detecting Minimal Residual Disease

    Lanny Kirsch, MD

    SVP, Translational Medicine, Adaptive Biotechnologies

  • Use of Imaging Biomarkers for Immunotherapy

    Ron Korn, MD, PhD

    Founder, Chairman and Chief Medical Officer, Imaging Endpoints

  • Neoantigen Approaches for Biomarkers

  • Emerging Concepts for the Detection of Minimal Residual Disease using Liquid Biopsies

    Jonathan Wan, MD/PhD
    Cancer Research UK Cambridge Institute

2018 Agenda

  • New Trends & Collaborations Plenary Session

  • The BioCentury Report on Industry Trends

    Simone Fishburn, PhD

    Editor, BioCentury Innovations

  • The Endpoint News Report

    John D Carroll

    Editor-in-Chief, Endpoints News

  • Cancer Moonshot Progress

    Greg Simon, JD

    Director/ Former Executive Director,
    Biden Cancer Initiative/ Former White House Cancer Task Force  

  • Immuno-Oncology Progress in China

  • IO Emerging Technologies & Innovative Solutions Plenary Session

    This plenary will showcase companies that have technologies and solutions that will help stakeholders in the IO field advance developments to provide treatment for cancer patients.

  • Business Aspects Plenary Session

  • Summary of IO Deals

    Jeff Bockman, PhD

    Principal, SVP, Oncology Practice Head, Defined Health

  • Large Pharma Perspective on IO Licensing Technology

  • Payer Perspective: How Do We Arrive at a New Pricing Model for IO? How a Payer Thinks we should get Community Consensus on a Pricing Model

  • Panel: Talent Management for IO


    Cissy Young, PhD, MBA

    Executive Director, Russell Reynolds Associates


    Jasmine Ferrer, DPhil

    Sr Client Partner, Biotech & Pharma Sector, Korn Ferry International

    Adam Millinger

    Founding Partner, ProMotion Career Management

2018 Agenda

  • Clinical Aspects Plenary Session

  • Balancing Benefit and Toxicity From Immunotherapeutics: How to Make Recommendations to Patients

    Jeffrey Weber, MD, PhD

    Deputy Director, Laura and Isaac Perlmutter Cancer Center, Co-Director, Melanoma Program & Head of Experimental Therapeutics, NYU Langone Medical Center

  • Maintenance Therapy in NSCLC

    Naiyer Rizvi, MD

    Director, Thoracic Oncology & Immunotherapeutics in Medical Oncology, NY Presbyterian / Columbia University Medical Center

  • Keytruda in Combo with Chemo in NSCLC

  • Update on Tecentriq (Atezolizumab) in Bladder Cancer

    Jonathan Rosenberg, MD

    Medical Oncologist, Memorial Sloan Kettering Cancer Center

  • The Role of PDL1 on Survival

  • FDA Viewpoint: Update on the Bladder Cancer Data with the Implications for Atezolizumab OS Failure for Both its Approval and That of Other Agents in Bladder Cancer

  • Changing Treatment Landscape in NSCLC

  • Pembrolizumab as a Broad Spectrum Anticancer Therapy Both as Mono and Combination Therapy

    Roy Baynes, MD, PhD

    SVP & Head, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories

  • Differences in Long Term Benefit Between Classes of Checkpoint Modulators

  • Trout Group Situation Room

    2017 trout group

  • Executive Fireside Chat

    Invited guest:

    George Yancopoulos, MD, PhD
    President & CSO, Regeneron

  • The Investor Lifecycle - How to Maneuver at Each Stage of Financing from Seed to Public Market

  • Panel: Immuno-Oncology CEOs Checking The Target

  • IO CEO Fireside Chats